Curative therapy for rectal cancer

References

• Deng Y, Chi P, Lan P, et al. Modified FOLFOX6 with or without radiation in neoadjuvant treatment of locally advanced rectal cancer: final results of the Chinese FOWARC multicenter randomized trial. J Clin Oncol. 2018;36(15_suppl):3502.
   PubMedGoogle Scholar
• Masi G, Vivaldi C, Fornaro L, et al. Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial. Eur J Cancer. 2019 Mar 1;110:32–41.
   PubMed Web of Science ®Google Scholar
• National Institutes of Health. Adjuvant therapy for patients with colon and rectum cancer. NIH Consensus Statement. 1990 Apr 16;8(4):1–25.
   Google Scholar
• Wolmark N, Wieand HS, Hyams DM, et al. Carcinoma of the rectum: national surgical adjuvant breast and bowel project protocol R-02. J Nat Cancer Inst. 2000;92(5–8):388.
   PubMedGoogle Scholar
• Fisher B, Wolmark N, Rockette H, et al. Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01. J Natl Cancer Inst. 1988;80(1):21–29.
   PubMed Web of Science ®Google Scholar
• Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med. 1991;324(11):709–715.
   PubMed Web of Science ®Google Scholar
• Trial SR, Cedermark B, Dahlberg M, et al. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med. 1997 Apr 3;336(14):980–987.
   PubMed Web of Science ®Google Scholar
• Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30(16):1926–1933.
   PubMed Web of Science ®Google Scholar
• Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731–1740.
   PubMed Web of Science ®Google Scholar
• Roh MS, Colangelo LH, O’Connell MJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol. 2009;27(31):5124–5130.
   PubMed Web of Science ®Google Scholar
• Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373(9666):811–820.
   PubMed Web of Science ®Google Scholar
• Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93(10):1215–1223.
   PubMed Web of Science ®Google Scholar
• Ngan SY, Burmeister B, Fisher RJ, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012;30(31):3827–3833.
   PubMed Web of Science ®Google Scholar
• Huang CM, Huang MY, Tsai HL, et al. An observational study of extending FOLFOX chemotherapy, lengthening the interval between radiotherapy and surgery, and enhancing pathological complete response rates in rectal cancer patients following preoperative chemoradiotherapy. Therap Adv Gastroenterol. 2016 Sep;9(5):702–712.
   PubMed Web of Science ®Google Scholar
• Rödel C, Liersch T, Becker H, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. 2012 Jul 1;13(7):679–687.
   PubMed Web of Science ®Google Scholar
• Deng Y, Chi P, Lan P, et al. Modified FOLFOX6 with or without radiation versus fluorouracil and leucovorin with radiation in neoadjuvant treatment of locally advanced rectal cancer: initial results of the Chinese FOWARC multicenter, open-label, randomized three-arm phase III trial. J clin oncol. 2016 Sep 20;34(27):3300–3307.
   PubMed Web of Science ®Google Scholar
• Wilkinson NW, Yothers G, Lopa S, et al. Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials. Ann Surg Oncol. 2010 Apr 1;17(4):959–966.
   PubMed Web of Science ®Google Scholar
• Bosset JF, Calais G, Mineur L, et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15(2):184–190.
   PubMed Web of Science ®Google Scholar
• Glynne-Jones R, Counsell N, Quirke P, et al. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol. 2014;25(7):1356–1362.
   PubMed Web of Science ®Google Scholar
• Breugom AJ, van Gijn W, Muller EW, et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol. 2015;26(4):696–701.
   PubMed Web of Science ®Google Scholar
• Sainato A, Cernusco Luna Nunzia V, Valentini V, et al. No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I-CNR-RT). Radiother Oncol. 2014;113(2):223–229.
   PubMed Web of Science ®Google Scholar
• Breugom AJ, Swets M, Bosset JF, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16(2):200–207.
   PubMed Web of Science ®Google Scholar
• Schmoll H-J, Haustermans K, Price T, et al. Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine ± oxaliplatin in locally advanced rectal cancer: final results of PETACC-6. J clin oncol. 2018;36:3500.
   Web of Science ®Google Scholar
• Hong YS, Nam BH, Kim KP, et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol. 2014;15(11):1245–1253.
   PubMed Web of Science ®Google Scholar
• Rodel C, Graeven U, Fietkau R, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16(8):979–989.
   PubMed Web of Science ®Google Scholar
• Garcia-Aguilar J, Chow OS, Smith DD, et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. 2015;16(8):957–966.
   PubMed Web of Science ®Google Scholar
• Fokas E, Allgäuer M, Polat B, et al. Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12. J clin oncol. 2019 Dec 1;37(34):3212–3222.
   PubMedGoogle Scholar
• Perez K, Safran H, Sikov W, et al. Complete neoadjuvant treatment for rectal cancer: the Brown University Oncology Group CONTRE Study. Am J Clin Oncol. 2017;40(3):283–287.
   PubMed Web of Science ®Google Scholar
• Dewdney A, Cunningham D, Tabernero J, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol. 2012;30(14):1620–1627.
   PubMed Web of Science ®Google Scholar
• Chua YJ, Barbachano Y, Cunningham D, et al. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol. 2010;11(3):241–248.
   PubMed Web of Science ®Google Scholar
• Marechal R, Vos B, Polus M, et al. Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. Ann Oncol. 2012;23(6):1525–1530.
   PubMed Web of Science ®Google Scholar
• Schou JV, Larsen FO, Rasch L, et al. Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before total mesorectal excision in patients with locally advanced rectal cancer. Ann Oncol. 2012;23(10):2627–2633.
   PubMed Web of Science ®Google Scholar
• Nogue M, Salud A, Vicente P, et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. Oncologist. 2011;16(5):614–620.
   PubMed Web of Science ®Google Scholar
• Fernandez-Martos C, Garcia-Albeniz X, Pericay C, et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trialdagger. Ann Oncol. 2015;26(8):1722–1728.
   PubMed Web of Science ®Google Scholar
• Cercek A, Roxburgh CSD, Strombom P, et al. Adoption of total neoadjuvant therapy for locally advanced rectal cancer. JAMA Oncol. 2018;4(6):e180071.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Trevisan F, Cabiddu M, et al. Total neoadjuvant therapy in rectal cancer: a systematic review and meta-analysis of treatment outcomes. Ann Surg. 2020;271(3):440–448.
   PubMed Web of Science ®Google Scholar
• Fokas E, Liersch T, Fietkau R, et al. Downstage migration after neoadjuvant chemoradiotherapy for rectal cancer: the reverse of the Will Rogers phenomenon? Cancer. 2015 Jun 1;121(11):1724–1727.
   PubMed Web of Science ®Google Scholar
• Martin ST, Heneghan HM, Winter DC. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. InDatabase of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet]. Centre for Reviews and Dissemination (UK); 2012.
   Google Scholar
• Maas M, Nelemans PJ, Valentini V, et al. Adjuvant chemotherapy in rectal cancer: defining subgroups who may benefit after neoadjuvant chemoradiation and resection: a pooled analysis of 3,313 patients. Int J Cancer. 2015 Jul 1;137(1):212–220.
   PubMed Web of Science ®Google Scholar
• Appelt AL, Vogelius IR, Pløen J, et al. Long-term results of a randomized trial in locally advanced rectal cancer: no benefit from adding a brachytherapy boost. Int J Radiat Oncol* Biol* Phys. 2014 Sep 1;90(1):110–118.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Borgonovo K, Cabiddu M, et al. Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials. J Gastrointest Oncol. 2017 Feb;8(1):39.
   PubMed Web of Science ®Google Scholar
• Park IJ, You YN, Agarwal A, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J clin oncol. 2012 May 20;30(15):1770.
   PubMed Web of Science ®Google Scholar
• Tulchinsky H, Shmueli E, Figer A, et al. An interval> 7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease–free survival in patients with locally advanced rectal cancer. Ann Surg Oncol. 2008 Oct 1;15(10):2661–2667.
   PubMed Web of Science ®Google Scholar
• Kalady MF, de Campos-lobato LF, Stocchi L, et al. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg. 2009 Oct 1;250(4):582–589.
   PubMed Web of Science ®Google Scholar
• Moore HG, Gittleman AE, Minsky BD, et al. Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum. 2004 Mar 1;47(3):279–286.
   PubMed Web of Science ®Google Scholar
• Zeng WG, Zhou ZX, Liang JW, et al. Impact of interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer on surgical and oncologic outcome. J Surg Oncol. 2014 Sep;110(4):463–467.
   PubMed Web of Science ®Google Scholar
• Habr-Gama A, Perez RO, Sabbaga J, et al. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period. Dis Colon Rectum. 2009 Dec 1;52(12):1927–1934.
   PubMed Web of Science ®Google Scholar
• Habr-Gama A, Sabbaga J, Gama-Rodrigues J, et al. Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management? Dis Colon Rectum. 2013 Oct 1;56(10):1109–1117.
   PubMed Web of Science ®Google Scholar
• Myerson RJ, Tan B, Hunt S, et al. Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer. Int J Radiat Oncol* Biol* Phys. 2014 Mar 15;88(4):829–836.
   PubMed Web of Science ®Google Scholar
• Garcia-Aguilar J, Smith DD, Avila K, et al. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multi-center, non-randomized phase II prospective trial. Ann Surg. 2011 Jul;254(1):97.
   PubMed Web of Science ®Google Scholar
• Garcia-Aguilar J, Marcet J, Coutsoftsides T. Impact of neoadjuvant chemotherapy following chemoradiation on tumor response, adverse events, and surgical complications in patients with advanced rectal cancer treatment with TME. J Clin Oncol. 2011 May 20;29(15 suppl):3514.
   Google Scholar
• Habr-Gama A, Gama-Rodrigues J, São Julião GP, et al. Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control. Int J Radiat Oncol* Biol* Phys. 2014 Mar 15;88(4):822–828.
   PubMed Web of Science ®Google Scholar
• Smith JD, Ruby JA, Goodman KA, et al. Nonoperative management of rectal cancer with complete clinical response after neoadjuvant therapy. Ann Surg. 2012 Dec 1;256(6):965–972.
   PubMed Web of Science ®Google Scholar
• Sposato LA, Lam Y, Karapetis C, et al. Observation of “complete clinical response” in rectal cancer after neoadjuvant chemoradiation: the Flinders experience. Asia‐Pacific J Clin Oncol. 2018 Dec;14(6):439–445.
   PubMed Web of Science ®Google Scholar
• van der Valk MJ, Hilling DE, Bastiaannet E, et al. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet. 2018 Jun 23;391(10139):2537–2545.
   PubMed Web of Science ®Google Scholar
• Conroy T, Lamfichekh N, Etienne PL, et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: final results of PRODIGE 23 phase III trial, a UNICANCER GI trial. Journal of Clinical Oncology. 2020 May 23;38(15_suppl): 4007–4007.
   Web of Science ®Google Scholar
• Garcia-Aguilar J, Patil S, Kim JK, et al. OPRA Consortium. Preliminary results of the organ preservation of rectal adenocarcinoma (OPRA) trial. Journal of Clinical Oncology. 2020 May 23;38(15_suppl): 4008–4008,
   Web of Science ®Google Scholar
• Hospers G, Bahadoer RR, Dijkstra EA, et al. Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: the randomized RAPIDO trial. Journal of Clinical Oncology. 2020 May 20;38(15_suppl): 4006–4006.
   Google Scholar
• Smith N, Brown G Preoperative staging of rectal cancer. Acta oncologica. 2008 Jan 1;47(1):20–31.
   PubMed Web of Science ®Google Scholar
• Blomqvist L, Glimelius B. The ‘good’, the ‘bad’, and the ‘ugly’ rectal cancers. Acta Oncol. 2008;47:5–8.
   PubMed Web of Science ®Google Scholar